Clinical trial · no report yet · Phase 2
AZUR-1
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
- NCT05723562 ↗
- Active, not recruiting
- GlaxoSmithKline
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Neoplasms, Rectal
- Interventions
- Dostarlimab
- Arms
- Dostarlimab monotherapy · Experimental
- Enrollment
- 154
- Primary outcomes
- Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR)
- Sponsor
- GlaxoSmithKline
- Start
- Apr 3, 2023
- Primary completion
- Nov 2, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05723562 · updated May 26, 2026